Table S1. Emetogenic potential of intravenous antineoplastic agents.
| Emetogenic level | Agent |
| High emetic risk | Carmustine |
| Cisplatin | |
| Cyclophosphamide (>1,500 mg/m2) | |
| Dacarbazine | |
| Actinomycin | |
| Mustard | |
| Streptozotocin | |
| Cyclophosphamide + Daunorubicin | |
| Cyclophosphamide + Epirubicin | |
| Cyclophosphamide + Idarubicin | |
| Cyclophosphamide + Doxorubicin | |
| Azacitidine | |
| Alemtuzumab | |
| Bendamustine | |
| Carboplatin | |
| Clofarabine | |
| Moderate emetic risk | Cyclophosphamide (≤1,500 mg/m2) |
| Cytarabine (>1 g/m2) | |
| Daunorubicin | |
| Adriamycin | |
| Epirubicin (≤90 mg/m2) | |
| Idarubicin | |
| Ifosfamide | |
| Oxaliplatin (>75 mg/m2) |
Emetic risk was based on the American Society of Clinical Oncology (ASCO) 2006 (21) and the National Comprehensive Cancer Network (NCCN) guidelines for antiemetic therapy 2007 (22).